Patents Assigned to Merck
  • Sol-gel-based printable doping media which inhibit parasitic diffusion for the local doping of silicon wafers
    Publication number: 20180062022
    Abstract: The present invention relates to a novel printable paste in the form of a hybrid gel based on precursors of inorganic oxides which can be used in a simplified process for the production of solar cells, where the hybrid gel according to the invention functions both as doping medium and also as diffusion barrier.
    Type: Application
    Filed: March 24, 2016
    Publication date: March 1, 2018
    Applicant: Merck Patent GmbH
    Inventors: Oliver DOLL, Ingo KOEHLER, Sebastian BARTH
  • PYRAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS
    Publication number: 20180057480
    Abstract: The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    Type: Application
    Filed: March 21, 2016
    Publication date: March 1, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Dong-Ming Shen, Jonathan E. Wilson, Meng Yang, Dann Parker, Zack Zhiqiang Guo, Alejandro Crespo, Deping Wang, Troy McCracken
  • LIQUID-CRYSTALLINE MEDIA HAVING HOMEOTROPIC ALIGNMENT
    Publication number: 20180057743
    Abstract: The present invention relates to liquid-crystalline media (LC media) having negative or positive dielectric anisotropy, comprising a low-molecular-weight component and a polymerizable component. The polymerizable component comprises self-aligning, polymerizable mesogens (polymerizable self-alignment additives) which effect homeotropic (vertical) alignment of the LC media at a surface or the cell walls of a liquid-crystal display (LC display). The invention therefore also encompasses LC displays having homeotropic alignment of the LC medium without alignment layers. The invention discloses novel structures for self-alignment additives which have a certain position of the functional groups.
    Type: Application
    Filed: November 3, 2017
    Publication date: March 1, 2018
    Applicant: Merck Patent GmbH
    Inventors: Graziano ARCHETTI, Izumi SAITO, Rocco FORTTE, Thorsten KODEK
  • METHODS FOR THE TREATMENT AND PROPHYLAXIS OF HIV AND AIDS
    Publication number: 20180055867
    Abstract: The present invention is directed to methods for inhibition of HIV reverse transcriptase, treatment of infection by HIV, prophylaxis of infection by HIV, and the treatment, prophylaxis and/or delay in the onset or progression of AIDS or ARC by administering a compound of structural Formula I or a pharmaceutically acceptable salt or co-crystal thereof, wherein X is —F or —Cl, less frequently than once daily.
    Type: Application
    Filed: February 10, 2017
    Publication date: March 1, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Daria Hazuda, Michael D. Miller, Jay A. Grobler, Deborah Anne Nicoll-Griffith
  • Oxoquinazolinyl-butanamide derivatives
    Patent number: 9901577
    Abstract: Compounds of the formula I in which R1-R3 and Z have the meanings indicated in Claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: February 27, 2018
    Assignee: MERCK PATENT GMBH
    Inventors: Dieter Dorsch, Hans-Peter Buchstaller
  • CARBOXAMIDE INHIBITORS OF IRAK4 ACTIVITY
    Publication number: 20180051027
    Abstract: The present invention relates to carboxamide inhibitors of IRAK4 of formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.
    Type: Application
    Filed: March 7, 2016
    Publication date: February 22, 2018
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: JONGWON LIM, MICHAEL D. ALTMAN, MATTHEW L. CHILDERS, CRAIG R. GIBEAU, GINNY DAI HO, HONCHUNG TSUI
  • PYRROLOPYRIDAZINE INHIBITORS OF IRAK4 ACTIVITY
    Publication number: 20180051029
    Abstract: The present invention relates to pyrrolopyridazine inhibitors of IRAK4 of formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.
    Type: Application
    Filed: March 7, 2016
    Publication date: February 22, 2018
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: JONGWON LIM, MICHAEL D. ALTMAN, JASON D. BRUBAKER, CRAIG R. GIBEAU
  • Process for the production of solar cells using printable doping media which inhibit the diffusion of phosphorus
    Publication number: 20180053873
    Abstract: The present invention relates to a novel printable medium in the form of a hybrid sol and/or gel based on precursors of inorganic oxides for use in a simplified process for the production of solar cells, in which the medium according to the invention functions both as doping medium and also as diffusion barrier.
    Type: Application
    Filed: March 24, 2016
    Publication date: February 22, 2018
    Applicant: Merck Patent GmbH
    Inventors: Oliver DOLL, Ingo KOEHLER, Sebastian BARTH
  • PYRAZOLOPYRIMIDINE INHIBITORS OF IRAK4 ACTIVITY
    Publication number: 20180051028
    Abstract: The present invention relates to pyrazolopyrimidine inhibitors of IRAK4 of formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.
    Type: Application
    Filed: March 7, 2016
    Publication date: February 22, 2018
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: JONGWON LIM, MICHAEL D. ALTMAN, JASON D. BRUBAKER, CRAIG R. GIBEAU
  • PYRROLOTRIAZINE INHIBITORS OF IRAK4 ACTIVITY
    Publication number: 20180051030
    Abstract: The present invention relates to pyrrolotriazine inhibitors of IRAK4 of formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.
    Type: Application
    Filed: March 7, 2016
    Publication date: February 22, 2018
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: JONGWON LIM, MICHAEL D. ALTMAN, JASON D. BRUBAKER, CRAIG R. GIBEAU
  • Materials for Organic Electroluminescent Devices
    Publication number: 20180051206
    Abstract: The present invention relates to a compound of formula (I) or (II), which is suitable for use as functional material in an electronic device, in particular as emitter material in an organic electroluminescent device.
    Type: Application
    Filed: February 26, 2016
    Publication date: February 22, 2018
    Applicant: Merck Patent GmbH
    Inventors: Beate Burkhart, Holger Heil, Lara-lsabel Rodriguez, Sebastian Meyer, Amandine Darsy, Rouven Linge
  • THIENOPYRAZINE INHIBITORS OF IRAK4 ACTIVITY
    Publication number: 20180051035
    Abstract: The present invention relates to thienopyrazine inhibitors of IRAK4 of formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.
    Type: Application
    Filed: March 7, 2016
    Publication date: February 22, 2018
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: JONGWON LIM, MICHAEL D. ALTMAN, CRAIG R. GIBEAU
  • FACTOR XIa INHIBITORS
    Publication number: 20180050022
    Abstract: The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
    Type: Application
    Filed: August 21, 2017
    Publication date: February 22, 2018
    Applicant: MERCK SHARP & DOHME CORP
    Inventors: Dong-Ming Shen, Rongze Kuang, Puneet Kumar, Joseph L. Duffy, Cheng Zhu, Amjad Ali, Meng Yang, John S. Debenham
  • PHOSPHATE SUBSTITUTED QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS
    Publication number: 20180051043
    Abstract: The present invention relates to Phosphate Substituted Quinolizine Derivatives of Formula (I): and pharmaceutically acceptable salts or prodrug thereof, wherein X, Y, R1, R2, R3, R4, R5, R9 and R10 are as defined herein. The present invention also relates to compositions comprising at least one Phosphate Substituted Quinolizine Derivative, and methods of using the Phosphate Substituted Quinolizine Derivatives for treating or preventing HIV infection in a subject.
    Type: Application
    Filed: March 25, 2016
    Publication date: February 22, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Tao Yu, Sherman T. Waddell, John A. McCauley, Thomas H. Graham, Hong Li, Izzat Raheem, Jay A. Grobler
  • TrkA kinase inhibitors, compositions and methods thereof
    Patent number: 9896447
    Abstract: The present invention is directed to benzyl urea compounds of formula (I) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence may be useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor Trk-A, Trk-B and/or Trk-C.
    Type: Grant
    Filed: September 17, 2014
    Date of Patent: February 20, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Andrew J. Cooke, Craig A. Stump, Xu-Fang Zhang, Chun Sing Li, Qinghua Mao
  • Method for producing siliceous film and polysilazane coating treatment liquid used therefor
    Patent number: 9896764
    Abstract: The present invention provides a method for forming a siliceous film. According to the method, a siliceous film having a hydrophilic surface can be formed from a polysilazane compound at a low temperature. In the method, a composition containing a polysilazane compound and a silica-conversion reaction accelerator is applied on a substrate surface to form a polysilazane film, and then a polysilazane film-treatment solution is applied thereon so that the polysilazane compound can be converted into a siliceous film at 300° C. or less. The polysilazane film-treatment solution contains a solvent, hydrogen peroxide and an alcohol.
    Type: Grant
    Filed: September 2, 2010
    Date of Patent: February 20, 2018
    Assignee: Merck Patent GmbH
    Inventors: Yuki Ozaki, Masanobu Hayashi
  • A PHOTOSENSITIVE COMPOSITION AND COLOR CONVERTING FILM
    Publication number: 20180046080
    Abstract: The present invention relates to a photosensitive composition comprising at least one nanosized fluorescent material and polysiloxane, to a color conversion film, and to a use of the color conversion film in an optical device. The invention further relates to an optical device comprising the color conversion film and a method for preparing the color conversion film and the optical device.
    Type: Application
    Filed: February 5, 2016
    Publication date: February 15, 2018
    Applicants: Merck Patent GmbH, AZ Electronic Materials (Luxembourg) S.a.r.l.
    Inventors: Masayoshi SUZUKI, Tadashi KISHIMOTO, Yuki HIRAYAMA, Stephan DERTINGER, Toshiaki NONAKA, Daishi YOKOYAMA
  • PROCESS FOR PREPARING RECOMBINANT INSULIN USING MICROFILTRATION
    Publication number: 20180044395
    Abstract: The use of two tandem microfiltration (MF) steps in a process for making recombinant insulin is described. The two MF steps in a single downstream purification unit operation reduce both soluble and insoluble impurities and exchange the insulin product into a suitable buffer for downstream purification.
    Type: Application
    Filed: March 3, 2016
    Publication date: February 15, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Sean S. Gant, Michael J. Iammarino, Kristi Kerchner, Michael A. Rauscher, David J. Roush, Christopher H. Smith, Martin Chandler, Matthew Petroff
  • LIQUID-CRYSTAL MEDIUM
    Publication number: 20180044591
    Abstract: The present invention relates to a liquid crystal (LC) medium comprising a polymerizable compound, to a process for its preparation, to its use for optical, electro-optical and electronic purposes, in particular in LC displays, especially in an LC display of the polymer sustained alignment (PSA) type, and to an LC display, especially a PSA display, comprising it.
    Type: Application
    Filed: August 4, 2017
    Publication date: February 15, 2018
    Applicant: MERCK PATENT GMBH
    Inventors: Ji-Won JEONG, Eun-Kyu LEE, Hyun-Jin YOON, Min-Ok JIN, Yong-Kuk YUN
  • COMBINATION OF A PD-1 ANTAGONIST AND VORINOSTAT FOR TREATING CANCER
    Publication number: 20180044418
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and suberoylanilide hydroxamic acid (SAHA), and the use of the combination therapies for the treatment of caner.
    Type: Application
    Filed: March 15, 2016
    Publication date: February 15, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Elaine M. Pinheiro, Ronan O'Hagan, Venkataraman Sriram, Joe Phillips